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A B S T R A C T
Osteosarcoma is a primary malignant bone tumour, for which no improvement in survival rate has been made
since the nineteen seventies. We set out to systemically identify the in vitro studies performed in the past two
decades describing potential future therapies. Strikingly, we obtained a total of 5282 PubMed hits on this
subject. The amount of publications has increased almost exponentially over the past few years. Studies from
Chinese institutes are mainly responsible for this huge increase, accounting for 53% of the publications in 2015.
Approximately 1/3 of all drugs described in the past three years could be classified as traditional medicine.
Furthermore, it struck our attention that even though in such studies multiple cell lines are essential to represent
the heterogeneity in patients, many studies were performed with only one or two cell lines, i.e. U-2 OS or MG-63.
These cells are fast growing, facilitating rapid experimental application but also boosting drug responsiveness.
This probably explains why so many in vitro studies have been published for this relatively rare disease.
Furthermore, it illustrates the current publication pressure, especially in China.
1. Introduction
Osteosarcoma is the most frequent primary malignant bone tumour.
It has a peak incidence between 10 and 14 year of age and only 30% of
all osteosarcomas occur in individuals aged> 40 [1]. Osteosarcoma is a
rare disease, with an annual incidence rate of approximately 4.4 per 106
for people aged 0–24 years [1]. Several subtypes of osteosarcoma can
be distinguished, of which conventional high-grade central, or intra-
medullary osteosarcoma, is by far the most common (75% of the cases).
Osteosarcoma is characterized by the production of osteoid matrix and
is located mostly at the metaphysis of long bones. In addition to surgery
patients receive intensive pre- and post-operative chemotherapy [2].
Although neo-adjuvant chemotherapy has markedly improved out-
come, since its introduction in the 70ties survival has reached a plateau
of about 60–70% [3]. Especially osteosarcoma presenting with metas-
tases at diagnosis has a particular poor outcome. Therefore, new
treatment options are needed. As osteosarcoma is a rare disease,
international collaborations are essential for the conduction of clinical
trials. The European and American osteosarcoma study group (EUR-
AMOS), started its first trial in 2005, in which 2260 patients from 326
centres across 17 countries were enrolled [2]. This largest osteosarcoma
study to date could be achieved by a committed collaboration between
four well established study groups. However, due to the absence of
consensus and regional differences in compound approval, a second
study has not emerged yet, which is especially discouraging now this
successful worldwide network has been established [2].
2. Almost exponential increase in amount of osteosarcoma in vitro
studies
To see how the quantity of osteosarcoma in vitro studies developed
overtime, we set out to systematically identify all the drugs that have
been tested on osteosarcoma cells in vitro in the past two decades. A
PubMed search strategy was compiled which can be found in
Supplementary data 1. To our surprise, we got a total of 5282 hits in
PubMed. It struck our attention that the number of publications on
treatment of osteosarcoma cell lines with various compounds has
increased almost exponentially (Fig. 1A). After importing these PubMed
hits in EndNote X7, we obtained an indication of how the amount of
publications developed in China, the USA, India, Australia, Canada and
Europe (defined as countries that are in the Schengen Area and/or the
European Union) in the past few years by searching for these countries
in the authors address box. The majority of the publications came from
China, Europe or the USA. The amount of publications from the USA
showed a minor increase, from 45 in 1996 to 73 in 2015, whereas the
amount of publication from Europe increased substantially from 35 in
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1996 to 176 in 2015. Strikingly, the amount of publications from China
rose from 1 to 359, thereby mainly being responsible for the huge
increase in publications observed in the last few years. China has been
the leading country since 2012, and 53% of the publications from 2015
involved Chinese institutes; this is a much higher proportion than
reported for other research areas such as haematology research [4]. We
read all the abstracts of the hits of the past three years (n=1755), and
categorized them based on non-osteosarcoma (n=297, many studies on
Fig. 1. The amount of hits from PubMed searches per year. A: The amount of osteosarcoma in vitro studies greatly increased in the past few years, with an increased proportion of articles
with Chinese authors. B: Amount of PubMed hits per year for U-2 OS (osteosarcoma), MG-63 (osteosarcoma) and HT-1080 (fibrosarcoma) demonstrates that the exponential increase in in
vitro studies is not identified in other sarcomas.
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other cancers metastasizing to the bone), no in vitro study (n=179), no
drugs study (n=596, many studies performed siRNA knockdown only)
and no inhibitory effect (n=126), leaving us with 560 studies from the
last three years, a relatively large number when considering the
rareness of this disease. Interestingly, approximately 1/3 of the
compounds could be classified as traditional medicine, of which over
80% was published by Chinese authors. For example, we encountered
several compounds such as Evodiamine, a chemical extracted from the
Tetradium genus of plants [5,6] and crude extracts of Rheum palmatum
L., the root of Chinese rhubarb [7].
3. The use of a single cell line
Remarkably, many studies were performed with only one cell line,
either U-2 OS or MG-63. Due to the high heterogeneity of osteosarcoma,
studying a panel of cell lines instead of a single cell line is essential for
eventual clinical applicability. U-2 OS and MG-63 are both ATCC cell
lines established in 1964 and 1977 respectively. Searching PubMed for
U-2 OS (and U2OS/U2-OS/U-2-OS) and MG-63 (and MG63) identified
respectively 1449 and 2564 publications from 1996 to 2015, while the
combination only resulted in 163 PubMed hits. Determining the
amount of publications per year and per country for these cell lines
as described above further demonstrated the almost exponential
increase in publications with osteosarcoma cell lines attributable to
studies from Chinese institutes (Fig. 1B). To compare these results with
another ATCC sarcoma cell line with a comparable amount of total
publications, we performed an identical search for HT-1080 (fibrosar-
coma), in which we did not see this trend (Fig. 1B), demonstrating that
this is not a trend observed in all ATCC sarcoma cell lines.
U-2 OS and MG-63 are ubiquitously applied also outside the
osteosarcoma field for general cell biology studies because they are
among the few human cell lines that are relatively susceptible to
transfection. In addition, these cells grow rapidly facilitating experi-
mental application but also boosting drug responsiveness [8]. This
probably explains why so many in vitro studies have been published for
this relatively rare disease.
4. A researcher's perspective
There may be a jewel hidden in this avalanche of studies, but it is
difficult to discern due to the huge quantity of papers using question-
able designs. If in vitro studies are performed, researchers should always
include a panel of cell lines to represent the tumour heterogeneity in
osteosarcoma patients. As a researcher, it is impossible to keep track of
all the research that is being published, which may lead to missing
promising therapeutic targets. The publication of these relatively easy
executable studies is obviously fed by the incentive of “publish or
perish”, but it keeps scientists occupied with often irrelevant work, it
usurps financial budgets and obscures relevant investigations. Other
major drivers of the enormous increase in research papers is the
substantial increase in the number of academic journals [9]. Aggressive
editor's requests to submit manuscripts to new journals keep filling a
scientist's mailbox, which can be quite disturbing. This trend to prevail
quantity over quality is occupying precious time from editors and
reviewers. Currently, the Science Citation Index is used for medical
career evaluation in the majority of large Chinese hospitals, resulting in
a huge pressure of Chinese medical doctors to publish articles and an
increase in number of publishing scientists [10,11]. Therefore, it is
essential that the evaluation system on research performance will be
changed with the focus shifted from quantity to quality as was recently
again advocated that bibliometrics are warping science [12]. Our
analysis of in vitro osteosarcoma studies illustrates the effect of the
increased publication pressure since the convenience of osteosarcoma
cell lines renders them into low hanging fruit but results in studies with
limited scientific value, which constrains solutions for this deadly
disease that affects young patients.
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